Aligos Therapeutics (ALGS) Liabilities and Shareholders Equity (2019 - 2026)

Aligos Therapeutics has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $64.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 57.16% year-over-year to $64.6 million; the trailing twelve-month figure through Mar 2026 stood at $397.6 million (down 4.9% YoY), and the FY2025 full-year result was $88.5 million, up 26.31% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $64.6 million, down from $88.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $210.5 million in Q1 2022, with the low at $64.6 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $124.3 million across 5 years, with a median of $121.7 million in 2023.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity climbed 26.31% — and 2026, when it slumped 57.16%.
• Aligos Therapeutics' Liabilities and Shareholders Equity stood at $146.7 million in 2022, then increased by 3.3% to $151.5 million in 2023, then slumped by 53.74% to $70.1 million in 2024, then rose by 26.31% to $88.5 million in 2025, then dropped by 27.08% to $64.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $64.6 million (Q1 2026), $88.5 million (Q4 2025), and $109.8 million (Q3 2025), per Business Quant data.